about
Th17 Cells Pathways in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders: Pathophysiological and Therapeutic ImplicationsAntibodies as Mediators of Brain PathologyImmunology of neuromyelitis optica: a T cell-B cell collaborationRestoring immune tolerance in neuromyelitis optica: Part IOptic neuritis in neuromyelitis optica.Experimental models of neuromyelitis optica.The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica.Early loss of oligodendrocytes in human and experimental neuromyelitis optica lesions.Inhibitor(s) of the classical complement pathway in mouse serum limit the utility of mice as experimental models of neuromyelitis optica.Brain-reactive antibodies and disease.Pathogenic aquaporin-4 reactive T cells are sufficient to induce mouse model of neuromyelitis optica.Experimental Neuromyelitis Optica Induces a Type I Interferon Signature in the Spinal Cord.Highly encephalitogenic aquaporin 4-specific T cells and NMO-IgG jointly orchestrate lesion location and tissue damage in the CNS.Serum peptide reactivities may distinguish neuromyelitis optica subgroups and multiple sclerosis.Cross-immunoreactivity between bacterial aquaporin-Z and human aquaporin-4: potential relevance to neuromyelitis optica.Aquaporin 4-specific T cells and NMO-IgG cause primary retinal damage in experimental NMO/SDIntrastriatal injection of interleukin-1 beta triggers the formation of neuromyelitis optica-like lesions in NMO-IgG seropositive ratsTolerance checkpoint bypass permits emergence of pathogenic T cells to neuromyelitis optica autoantigen aquaporin-4.Review of Animal Models of Neuromyelitis Optica.Marked central nervous system pathology in CD59 knockout rats following passive transfer of Neuromyelitis optica immunoglobulin G.Deletional tolerance prevents AQP4-directed autoimmunity in mice.Autoimmune epilepsiesPlasma exchange in severe attacks of neuromyelitis optica.Pathogenic and physiological autoantibodies in the central nervous system.T cell-activation in neuromyelitis optica lesions plays a role in their formation.Müller cells and retinal axons can be primary targets in experimental neuromyelitis optica spectrum disorder.Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients.T cells targeting neuromyelitis optica autoantigen aquaporin-4 cause paralysis and visual system injury.The Role of Brain-Reactive Autoantibodies in Brain Pathology and Cognitive Impairment.Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4.Where Do AQP4 Antibodies Fit in the Pathogenesis of NMO?Neuromyelitis Optica: Deciphering a Complex Immune-Mediated Astrocytopathy.Combination of cyclosporine A with corticosteroids is effective for the treatment of neuromyelitis optica.Comprehensive analysis of patients with neuromyelitis optica spectrum disorder (NMOSD) combined with chronic hepatitis B (CHB) infection and seropositive for anti-aquaporin-4 antibody.CD8-Positive T-Cell Leukoencephalitis With Astrocytopathy Clinically Presenting as Neuromyelitis Optica.Mechanisms for lesion localization in neuromyelitis optica spectrum disorders.NMO-IgG and AQP4 Peptide Can Induce Aggravation of EAMG and Immune-Mediated Muscle Weakness.Neuromyelitis opticaNeuromyelitis optica should be classified as an astrocytopathic disease rather than a demyelinating disease
P2860
Q26768649-BF7F046B-CA87-4C99-BB26-D61A1D452DE0Q26780374-AE815BA1-5FBB-4633-A1B3-47775B72412EQ27016045-367D830C-91A3-4C1E-9AAA-22A1DF4F4581Q28072382-88488DF5-4B87-4B34-9C6F-25EC3AC8CEA7Q30610471-7DD40B6B-29A9-4045-A377-857A99BDE3CEQ33785380-92B40176-7C36-45A2-A81A-F29F46BC06DEQ34392387-24655BC8-606B-48DF-9DD1-04AEBF23AFCFQ34497097-FE73B9CB-D174-4CCC-9303-705A3DEAF770Q35013113-350109E5-3E0B-425D-99C5-78B75E577213Q35458567-D6316696-6AEB-4557-8143-234401DEC9A5Q35626822-556B9A6E-4100-4D31-A0AD-7269537BF1E1Q35962565-D412A813-8033-4D69-B208-7645FDE61F9AQ36303835-58EA6D48-7AEA-4A68-930F-129DACBA0154Q36562604-E46B220E-9FB4-4DB9-8F2B-ACB70EB413BBQ36650640-A7C9F428-8EEE-463E-80BD-0D130214549BQ37160320-77339A58-ADAE-4E2C-A09B-4413AFEF1F41Q37180238-4CCE3B0F-56D5-4C37-BB73-9D81E1B1AEE1Q37534144-54EC463E-5B96-4CC3-9F8B-39535D7F592CQ37588030-25DC9DF7-B74D-4EFF-B29D-73AE8C88F4E3Q37650971-EF3D60F3-CBB2-48B4-8618-A89FBBF4CEECQ37712394-055863C3-5F06-4379-91FA-BA2D1CCB771CQ37717429-2C86BA3A-652B-4B1C-AF9E-64F35432AA6DQ37999792-D33BBE44-7E03-4ADF-B91B-5B3A53D870ACQ38020957-E8B87A3C-0C50-4096-A5D0-C0047C087A75Q39039987-D37EE3AC-C058-458B-97AB-94AE9C41EFBFQ39201610-B2FCD92D-152A-43E0-9CD8-7AF55BBD736CQ41096503-85406750-90C3-4B11-B01A-1C9CD039107FQ41098721-4C59C694-5835-419C-B56F-D65E308C64C0Q41684146-3C0D7FE6-5DA0-4BE0-9B1D-247029A3F911Q42364252-04B000E2-77FB-434E-8A2F-08AD126C02B6Q42560864-364CF2AF-7974-4230-992D-C2F27507D26FQ42844764-A63CBA34-F265-4C77-A20E-5BE1CBD618E9Q45832517-4EE05811-61C6-46D6-B12B-221D964039B0Q47396320-7A54FC84-EE1C-4967-82B2-B9E69252822BQ47816982-95C12576-3F18-40D8-ABE1-EC5E6D7C5DE2Q49713173-FBB07E90-1748-4733-BCF3-75DDD9058C5AQ55384506-CE81B925-4ADF-48A6-900B-395BE993FFBBQ56986418-8231D7C7-7B47-4699-8B69-925906AD5F52Q57725942-BB685485-250F-49CC-B223-4B8230E1DCB2
P2860
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Pathogenic T cell responses against aquaporin 4.
@en
Pathogenic T cell responses against aquaporin 4.
@nl
type
label
Pathogenic T cell responses against aquaporin 4.
@en
Pathogenic T cell responses against aquaporin 4.
@nl
prefLabel
Pathogenic T cell responses against aquaporin 4.
@en
Pathogenic T cell responses against aquaporin 4.
@nl
P2093
P2860
P1476
Pathogenic T cell responses against aquaporin 4.
@en
P2093
Hans Lassmann
Isabella Wimmer
Kathrin Schanda
Kazuo Fujihara
Maja Kitic
Maria Pohl
Marie-Therese Fischer
Monika Bradl
Rakhi Sharma
Simone Mader
P2860
P2888
P356
10.1007/S00401-011-0824-0
P577
2011-04-06T00:00:00Z